Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Telmisartan × 1 year × Clear all
NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Tanta University

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Breast Neoplasms

NCT06815497 2026-01-28

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT06168487 2025-08-21

Telmisartan in Prostate Cancer

Dartmouth-Hitchcock Medical Center

Phase 1 Recruiting
36 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡